ADK levels may predict triciribine sensitivity in leukemia cells, Karolinska study finds
Start here
A study from Karolinska Institutet reports that leukemia cells with higher levels of the enzyme ADK (adenosine kinase) show greater sensitivity to the investigational drug triciribine. The mechanism is that ADK converts triciribine into its active intracellular form, so cells with more of the enzyme activate more of the drug. The finding points to ADK as a potential biomarker that could identify which patients are most likely to respond to triciribine. The work is based on leukemia cells in the laboratory; clinical validation in patients has not yet been demonstrated, and whether ADK measurement can guide treatment decisions remains an open question.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- Medical XpressHigher ADK levels track stronger triciribine effects in leukemia cells, pointing to a potential biomarker
A Karolinska Institutet study shows that leukemia cells with higher levels of the enzyme ADK are more sensitive to triciribine, because ADK converts triciribine into its active form inside the cell.
Coverage and heat for this story
Reports so far 1·Heat now 7·Peak heat 10 (Oct 20 04:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.